Takeshima, Masahiro
Sakurai, Hitoshi
Inada, Ken
Aoki, Yumi
Ie, Kenya
Kise, Morito
Yoshida, Eriko
Matsui, Kentaro
Utsumi, Tomohiro
Shimura, Akiyoshi
Okajima, Isa
Kotorii, Nozomu
Yamashita, Hidehisa
Suzuki, Masahiro
Kuriyama, Kenichi
Shimizu, Eiji
Mishima, Kazuo
Watanabe, Koichiro
Takaesu, Yoshikazu
Funding for this research was provided by:
The Ministry of Health, Labor and Welfare of Japan (21GC1016)
Article History
Received: 27 May 2023
Accepted: 24 May 2024
First Online: 18 June 2024
Declarations
:
: This study was approved by the Ethics Committee of St. Luke’s International University (No. 2021–604) and conducted in accordance with the Declaration of Helsinki. Online Informed consent was obtained from all participants prior to questionnaire access.
: Not Applicable.
: Masahiro Takeshima has received speaker’s honoraria from Takeda Pharmaceutical; Otsuka Pharmaceutical; Daiichi Sankyo Company; Sumitomo Pharma; Meiji Seika Pharma; Viatris Pharmaceuticals Japan; Janssen, MSD; Eisai, Ltd.; and Yoshitomi Pharmaceutical, outside the submitted work. Hitoshi Sakurai has received grants from Takeda Science Foundation and manuscript and speaker fees from Eisai, Takeda Pharmaceutical, Otsuka Pharmaceutical, Meiji Seika Pharma, Shionogi Pharma, Yoshitomiyakuhin, Sumitomo Pharma, Kyowa Pharmaceutical, and Lundbeck Japan. Dr. Ken Inada has received personal fees/grant support from Eisai, Eli Lilly, Janssen, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, MSD, Novartis, Otsuka, Shionogi, Sumitomo Pharma, and Yoshitomiyakuhin in the last three years outside the submitted work. Yumi Aoki declares no conflicts of interest. Kenya Ie has received speaker’s honoraria from Eisai and research grants from the Japanese Ministry of Health, Labour and Welfare (grant number: 18K15434, 22K15678) and the Japan Agency for Medical Research and Development (grant number: 21fk0108486h0001) outside the submitted work. Morito Kise declares no conflicts of interest. Eriko Yoshida declares no conflicts of interest. Kentaro Matsui has received speaker’s honoraria from Eisai, Mejiseika Pharma, MSD, Otsuka Pharmaceutical, Yoshitomi Pharmaceutical, and Takeda Pharmaceutical outside the submitted work. Tomohiro Utsumi received speaker’s honoraria from Eisai. Akiyoshi Shimura has received lecture fees from Sumitomo Pharma, Nobelpharma, and Eisai outside the submitted work. Isa Okajima received grants from NEC Solution Innovators Co., Ltd., and Infocom Co., lecture fees from Otsuka Pharmaceutical Co., Ltd.; MSD K.K.; and Eisai Co., Ltd., and consultation fees from NEC Solution Innovators Co., Ltd. and Suntory Wellness Ltd. outside the submitted work. Nozomu Kotorii has received speaker’s honoraria from Eisai, Takeda Pharmaceutical, MSD, Otsuka Pharmaceutical, Shionogi Pharma, and Janssen Pharmaceutical. Hidehisa Yamashita has received speaker’s honoraria from Eisai, Mochida, Takeda Pharmaceutical, and MSD outside the submitted work. Masahiro Suzuki has received research grants from Mochida Pharmaceutical and Shionogi Pharma; research grants and speaker’s honorarium from EA Pharma, Eisai, Otsuka Pharmaceutical, Sumitomo Pharma, and Takeda Pharmaceutical; speaker’s honorarium from Meiji Seika Pharma, MSD, Viatris, and Yoshitomi Pharmaceutical; and payment for expert testimony from Mochida Pharmaceutical outside the submitted work. Kenichi Kuriyama has received research grants from Otsuka Pharmaceutical and Shionogi Pharma; research grants and speaker’s honorarium from Meiji Seika Pharma, Eisai, MSD, Takeda Pharmaceutical, and Tsumura; and speaker’s honorarium from Yoshitomi Pharmaceutical, and Sumitomo Pharma outside the submitted work. Eiji Shimizu has received speaker’s honoraria from Mochida Pharmaceutical, KYOWA Pharmaceutical Industry, Astellas, Kyorin, and Dainippon Pharma, and research funding from Sumitomo Pharma outside the submitted work. Kazuo Mishima has received speaker’s honoraria from Eisai, Nobelpharma, Takeda Pharmaceutical, and MSD. Moreover, Kazuo Mishima has received research grants from Eisai, Sumitomo Pharma, Takeda Pharmaceutical, AMED (grant number: JP21dk0307103KM), and the Japanese Ministry of Health, Labour and Welfare (grant number: 19GC1012, 21GC0801) outside the submitted work. Koichiro Watanabe has received manuscript fees or speaker’s honoraria from Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Pharma, and Takeda Pharmaceutical and received research/grant support from Daiichi Sankyo, Eisai, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, MSD, Otsu-ka Pharmaceutical, Pfizer, Sumitomo Pharma, and Takeda Pharmaceutical. Moreover, Koichiro Watanabe is a consultant of Boehringer Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Luye Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical outside the submitted work. Yoshikazu Takaesu has received lecture fees from Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Otsuka Pharmaceutical, Meiji Seika Pharma, Kyowa Pharmaceutical, Eisai, MSD, and Yoshitomi and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, MSD, and Eisai outside the submitted work.